Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anterios, Inc.
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Anterios developed a proprietary needle-free topical delivery system for botulinum toxin and advanced several programs into Phase 2 clinical trials targeting crow’s feet, hyperhidrosis, and acne. Clinical studies demonstrated that their lead product ANT‑1207 was well tolerated and showed statistically significant efficacy in these indications. The company was acquired by Allergan in early 2016 to enhance Allergan's neurotoxin pipeline.[1][4][6]
- Therapeutic areas
- Dermatology
- Modalities
- Botulinum toxin (Type A)macromolecules[2][6]
- Industry
- Biotech
02
Partnerships
Allergan plc (acquirer)Eirion Therapeutics received non-exclusive rights to ANT‑1207 prior to the Allergan deal[4].
Beyond the preview
Go deeper on Anterios, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anterios, Inc..